Table 5.
Immunogenicity analysis in susceptible subjects.
| 5-dose PVRV-WIBP | 5-dose PVRV-LNCD | 4-dose PVRV-WIBP | p-value | |
|---|---|---|---|---|
| Pre-vaccination | 0 | 0 | 0 | / |
| Antibody titer, GMT (95%) | ||||
| 0:7:42/35a | 1.05 (0.90–1.22) | 0.7 (0.61–0.80) | 1.5 (1.30–1.72) | <.0001 |
| 0:14:42/35b | 35.36 (32.77–38.15) | 29.32 (26.98–31.84) | 36.55 (33.88–39.43) | .0001 |
| 14-day PWVc | 19.97 (18.73–21.30) | 15.28 (14.24–16.39) | 21.55 (20.30–22.89) | <.0001 |
| Seroconversion rate, % (95%) | ||||
| 0:7:42/35a | 71.43 (65.90–76.52) | 59.42 (53.70–64.95) | 83.5 (78.83–87.5) | <.0001 |
| 0:14:42/35b | 100 (98.76–100.00) | 100.0 (98.78–100.0) | 100 (98.84–100.0) | 1.0000 |
| 14-day PWVc | 100 (99.38–100.00) | 100.0 (99.40–100.0) | 100 (99.41–100.0) | 1.0000 |
a0:7:42/35, the GMT and seroconversion rate was based on the 7 days serological indicator after the first dose.
b0:14:42/35, the GMT and seroconversion rate was based on the 14 days serological indicator after the first dose was present. GMT,geometric mean titer.
c14-day PWV, the GMT and seroconversion rate was based 14 days after the whole vaccine schedule.